Filing Flows › Avalo Therapeutics (AVTX) › Q4 2025
Avalo Therapeutics (AVTX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 23, 2026
Avalo Therapeutics (AVTX) reported revenue of $59K for the fourth quarter 2025 (Q4 2025), -69% from a year earlier.
Avalo Therapeutics, Q4 2025: revenue $59K (-69% year over year), net loss $13.7M, operating cash flow −$14.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $59K | — | -69% |
| Operating profit | −$19.7M | — | — |
| Net earnings | −$13.7M | — | — |
| Operating cash flow | −$14.2M | — | — |
What changed
Revenue was $59K in Q4 2025, down 69% year over year.
Operating costs exceeded revenue by $19.7M, an operating margin of -33461.0%. Total costs grew 47% against a revenue fall of 69%. The fastest-growing cost line was Research & development (+62%). The quarter ended with a net loss of $13.7M. Non-operating items added $6.2M, -45% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$14.2M. Non-cash charges added back $16K of depreciation and amortization and $4.5M of share-based compensation. Working capital and other items used $5.0M.
Questions
What was Avalo Therapeutics' revenue in the fourth quarter 2025?
Avalo Therapeutics (AVTX) reported revenue of $59K for the fourth quarter 2025 (Q4 2025), -69% from a year earlier.
Source: Avalo Therapeutics 10-K on SEC EDGAR.